ATEK Medical Group

ATEK Medical Group specializes in innovative medical solutions that enhance patient care and operational efficiency, providing advanced medical devices and diagnostic tools for healthcare systems. ATEK Medical Group designs and manufactures medical devices and diagnostic tools for healthcare settings. The company was acquired by The MedTech Group, a portfolio company of KRG Capital, in November 2011. ATEK Medical is headquartered in Grand Rapids, US and has been focused on addressing critical healthcare needs since its inception.

ATEK Medical offers a range of medical solutions that focus on enhancing patient care and operational efficiency within healthcare settings. Their primary offerings include innovative medical devices and diagnostic tools aimed at improving patient monitoring and treatment. These products facilitate real-time data collection and analysis, thereby enhancing diagnostic accuracy and treatment effectiveness. ATEK Medical serves hospitals, outpatient facilities, and private medical practices across Europe, North America, and select regions in Asia, reflecting their commitment to research and development in the healthcare sector.

ATEK Medical's revenue model is based on direct sales of its flagship medical devices and diagnostic tools to healthcare institutions and professionals. Transactions occur through B2B partnerships, where hospitals and medical facilities procure products via one-time purchases or long-term supply agreements. Their pricing strategy includes tiered pricing based on volume purchases, enabling larger clients to benefit from lower costs per unit. Revenue is primarily generated from sales of core products essential to client operations, which sustains demand for ATEK Medical's offerings.

ATEK Medical is focused on developing new products and expanding into new markets. The company is actively designing innovative medical devices aimed for release in the near future, although specific dates have not been disclosed. Additionally, ATEK Medical plans to expand its market presence in Europe and Asia by 2013. The funding acquired during the recent deal in November 2011 will support these initiatives, enhancing their capabilities in product development and market expansion.